Skip to main content
Clinical Trials/NCT02084901
NCT02084901
Completed
Phase 4

Comparison of Biodegradable Stents: Orsiro and BioMatrix

Yonsei University1 site in 1 country12 target enrollmentMarch 2014

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
All-comer
Sponsor
Yonsei University
Enrollment
12
Locations
1
Primary Endpoint
Neointimal coverage at 3 month after stent implantation
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The use of a biodegradable polymer has the potential to reduce the sustained inflammatory response of the arterial wall, facilitating re-endothelialization and minimizing the risk of thrombus formation and late restenosis. In the study, we are going to two biodegradable polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by optical coherence tomography at 3 months after stent implantation.

The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The secondary endpoint is clinical outcomes up to 1 year.

Detailed Description

The use of a biodegradable polymer has the potential to reduce the sustained inflammatory response of the arterial wall, facilitating re-endothelialization and minimizing the risk of thrombus formation and late restenosis. In the study, we are going to two biodegradable polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by optical coherence tomography at 3 months after stent implantation. The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The secondary endpoint is clinical outcomes up to 1 year.

Registry
clinicaltrials.gov
Start Date
March 2014
End Date
March 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients ≥ 20 years old
  • Patients in the treatment of subjects with all-comer who are to undergo PCI

Exclusion Criteria

  • Pregnant women or women with potential childbearing
  • Life expectancy \< 1 year

Outcomes

Primary Outcomes

Neointimal coverage at 3 month after stent implantation

Time Frame: At 3 months after stent implantation

The percentage of stent uncoverage measured by optical coherence tomography

Study Sites (1)

Loading locations...

Similar Trials